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The Landscape of Antibiotic Resistance www.jasonschneider.com Bacteria are said to have "intrinsic resis tance" to an antibiotic when their normal characteristics render them immune to the antibiotic's mechanism of effect. Intrinsic resistance is not affected by misuse of anti biotics. In fact, it is valuable in determin ing which antibiotic will be most effective against a certain microbe. For example, the outer membrane of gramnegative bac teria makes them relatively impermeable to hydrophobic compounds such as macro lide antibiotics, thus conferring intrinsic resistance to these drugs. Some bacteria can also use temporary strategies in which different genes are expressed or suppressed in order to enable survival in the presence of antibiotics, with expression patterns returning to normal once the threat posed by those particular drugs has passed.
In contrast, bacteria may acquire resis tance to an antibiotic by taking on a new characteristic through gene mutation or the transfer of genetic material between bacteria. Acquired characteristics that can make bacteria resistant to an antibiotic include changes to the bacterial mem brane that prevent antibiotics from enter ing the cell. Bacteria may also use enzymes to break down antibiotics, or they may employ "eff lux pumps" to remove the antibiotic entirely or reduce its concentra tion below effective levels.
If a bacterium is able to perform more than one of these functions, it may be resistant to more than one type of anti biotic, resulting in multidrug resistance, according to P.M. Bennett, writing in the March 2008 issue of the British Journal of Pharmacology. At the same time, the possession of even a single form of efflux pump can lead to the export of-and protection against-more than one form of antibiotic, thus also conferring multi drug resistance, adds David McDowell, a professor of food studies at the University of Ulster.
Mutations are relatively rare, occur ring in only 1 event per 10 7 -10 10 bac teria, according to a review by Michael R. Mulvey and Andrew E. Simor in the 17 February 2009 issue of the Canadian Medical Association Journal. As an example, Mulvey and Simor pointed to isoniazid resistance among Mycobacterium tuberculo sis. "This form of resistance is not transfer able to other organisms," they wrote. "The probability of multiple resistance mutations occurring in a single organism is equal to the product of their individual probabili ties. This is the rationale behind the use of combination therapy for the management of tuberculosis."
Of greater concern are "promiscu ous" gene transfer systems that allow the sharing of genetic material between bac teria. One genetic transfer strategy is the exchange of conjugative plasmids. These circles of DNA, which are separate from the bacterial chromosome, can replicate independently and move between bacte ria carrying antibiotic resistance genes, thereby multiplying antibiotic resistance among successive generations within a bacterial colony. Bacteria may also acquire resistance genes through the spread of transposons or integrons, groups of linked genetic elements.
In the July 2008 issue of the Journal of Bacteriology, Michael Gillings and col leagues wrote that class 1 integrons (the most extensively studied type of integron) now appear in 40-70% of gramnegative pathogens in clinical and agricultural sam ples. "The rapid spread of class 1 integrons through gramnegative and, more recently, into grampositive species has been facili tated by their location on mobile DNA elements, such as plasmids and transpo sons, coupled with the selective advantage conferred by their associated antibiotic resistance genes," they wrote. The authors noted about 10% of sequenced bacterial genomes carry integrons.
In some instances, resistance mecha nisms are induced by the presence of an antibiotic, says José L. Martínez, a micro biologist at the Spanish National Center of Biotechnology, but in most cases resis tance arises when susceptible bacteria are killed by the antibiotic and only those resistant few prevail and reproduce. In other words, antibiotics don't cause resis tance. Instead, they select for resistant bacteria and increase the proportional prevalence.
Ironically, the impulse to scour equip ment and surfaces may sometimes end up worsening this situation, as M. Ann S. McMahon and colleagues pointed out in the January 2007 issue of Applied and Environmental Microbiology: "Detergents and solvents have been shown, among other compounds, to induce the [multiple antibiotic resistance] operon," they wrote, describing foodpreservation processes. "This operon regulates the expression of a large number of genes, including those coding for at least one broadspecificity eff lux pump (the arcAB eff lux pump), which are more strongly expressed under conditions of environmental stress. This suggests a direct linkage between environ mental stresses, such as those occurring in foods and the domestic environment, efflux pump expression, and the develop ment of antibiotic resistance." The authors suggest that the increased use of sublethal bacteriostatic food preservation methods (as opposed to bactericidal methods) may be contributing to antibiotic resistance among foodrelated pathogens.
Case in Point
The problem of antibiotic resistance has become widely known in large part because of the emergence of methicillinresistant Staphylococcus aureus (MRSA), an increas ingly common bacterial agent with fright ening consequences. Initially, most MRSA infections were contracted by hospital in patients suffering from other underlying conditions. Such infections were dubbed hospitalacquired MRSA (sometimes called healthcareassociated MRSA, and abbrevi ated in both cases as HAMRSA). Moreover, colonization with MRSA can persist even after several years. In a study reported in the 1 April 2009 issue of Clinical Infectious Diseases, Ari Robicsek and colleagues examined 1,564 patients after positive MRSA identification and then retested them over a 4year period. After one year, 48.8% of the patients were still colonized with MRSA. After four years, 21.2% were still colonized. The les son to be learned, according to the authors, is that "even in the fourth year after a positive clinical culture result, the risk of MRSA colonization does not subside to that of the general patient population."
Risk factors for acquiring HAMRSA include recent hospitalization, outpatient visits to the hospital, and nursing home admission. CAMRSA infections are also associated with antibiotic exposure, chronic illness, injection drug use, athletics A 247
(particularly contact sports such as wres tling or those that involve handling a com munal object such as a volleyball), or close contact with someone who has one of these characteristics or exposures. Any sharing of equipment, clothing, or athletic facilities, or skintoskin contact, also increases the likelihood of acquiring MRSA. However, HAMRSA and CAMRSA have started to blend, with traditional risk factors pre dicting infection less accurately.
Spotted in the Wild
In the 2001 report Hogging It! Estimates of Antimicrobial Abuse in Livestock, the Union of Concerned Scientists estimated that 70% of all antibiotics used in the United States-more than 24 million pounds per year-is routinely put in the food and water of healthy livestock. Antibiotics are used in feed animals to not only control disease but also improve metabolism and reduce dietary requirements by stimulating the growth of microbes that produce vitamins and amino acids. In a review in the May 2007 issue of EHP, Amy R. Sapkota and colleagues wrote that the practice of using antibiotics at non therapeutic levels "has been shown to select for antibiotic resistance in both commensal and pathogenic bacteria in a) the animals themselves; b) subsequent animalbased food products; and c) water, air, and soil samples collected around largescale animal feeding operations."
Veterinary antibiotics often are excret ed unchanged. In the April 2001 issue of Applied and Environmental Microbiology, for instance, J. C. CheeSanford and col leagues reported that up to 75% of tetra cycline administered to swine was excreted unaltered. The excreted drugs can persist in the environment, creating an opportu nity for resistance selection within exposed bacterial populations.
Animal waste handling practices vary considerably between farms, but generally include "land application," the spreading of waste on the soil surface as a fertilizer, which can result in contamination of soil and surface or ground water. Many con ventional farming operations also use waste lagoons, which provide an alternative route by which birds and insects can pick up antibioticresistant bacteria.
A study by Jay P. One of the first studies to closely exam ine the occurrence of MRSA on U.S. farms looked at two swine production systems. As reported by Tara C. Smith and colleagues in the 23 January 2009 edition of PLoS ONE, one farm had extremely high levels of the ST398 strain of MRSA in both its ani mal population (49% overall, with 100% occurrence in animals aged 9-12 weeks) and its workers (64%). Yet, none of the animals or workers in the second farming system had MRSA, which may have to do with the source of the animals. Smith explains, "Because the farms got their ani mals from different sources, we're guessing MRSA is moving via importation, bringing in pigs already colonized."
Pharmaceutical factories, themselves, can be another source of antibiotics enter ing the environment. As Meghan Hessen auer, an environmental scientist at the U.S. Environmental Protection Agency, points out, guidelines for pharmaceutical manu facturing wastes are geared toward the dis charge of chemicals used in the process of manufacturing rather than active pharma ceutical ingredients. This, she says, means "there is no regulation and no limits on antibiotics themselves."
Other Environmental Inputs
There are best management practices in place to prevent such industrial releases, says Hessenauer. Nevertheless, drugs are still making their way out of at least some manufacturing plants. In one survey of a wastewater treatment plant that received effluent from a penicillin G production facility, In one study, more than half of survey respondents reported flushing unused antibiotics down the toilet.
HOMES PHARMACEUTICAL FACTORIES
Current regulations address discharges of chemicals used to produce antibiotics but not antibiotics themselves that end up in plant effluent. Researchers are still evaluating how dis infectants and antibacterial products such as handsoap may impact antibiotic resis tance. In the April 2003 issue of Clinical Microbiology Reviews, Peter Gilbert and Andrew J. McBain wrote, "While the regu lar application and use of antimicrobial handwashing products have been noted to bring about a change in skin flora, this has not been associated with fluctuations in resistance." The following year, the Board of the International Scientific Forum on Home Hygiene issued a consensus state ment declaring "there is no evidence that biocide use has been a significant factor to date in the development of antibiotic resis tance in clinical practice-antibiotic mis use is the most significant causative factor."
The board noted, however, that "it is important to ensure that biocides are used responsibly as part of a good hygiene rou tine in the domestic setting in order to avoid the possibility of any impact on anti microbial resistance in the future." Indeed, the same holds true for communityscale hygiene. In the June 2004 issue of Eco toxicology and Environmental Safety, Richa Shrivastava reported that suboptimal chlo rination of water taken from India's River Gomti appeared to select for multidrug resistant Pseudomonas aeruginosa, an oppor tunistic pathogen.
On the Trail of the Resistance Footprint
David Patrick and James Hutchinson sug gested in the 17 February 2009 issue of the Canadian Medical Association Journal that a "resistance footprint" can help identify and measure antibiotic hazards. That is, every one connected with antibiotics through production, prescription, consumption, and disposal should consider their own poten tial contributions to the problem (their "footprint") as well as their role in prevent ing the spread of antibiotic resistance. Says Patrick, "The price for use of a specific course of antibiotics isn't necessarily suf fered by the person who takes them. In addition to potential therapeutic benefits from using antibiotics, there is a contribu tion to the selective pressure to resistance that affects other people."
Effective stewardship programs that promote the "resistance footprint" concept must acknowledge and address financial incentives for antibiotic use among farmers, on whom the burden of maintaining their herds rests and for whom financial con straints are often a great concern. Patrick says, "When I speak with food producers about pressure to get rid of antibiotics, they say a complication in North America is that we have a common food market between the United States and Canada, so if one side moves and perceives an economic disadvantage, they worry about putting themselves out of business. We need joint Canadian and U.S. support of agricultural regulations." If farmers could be shown the longerterm economic benefits of steward ship and "footprint" management, he adds, they might be more inclined to adopt strat egies that would limit use of antibiotics and reduce resistance.
So far, the majority of efforts to pre vent and reduce antibiotic resistance have occurred in the field of health care, with infectious disease practitioners and research ers leading a call to reduce unnecessary use of antibiotics and adopt other steward ship strategies. Hospitals have implemented stewardship programs that bring interested parties together to identify problem drugs, retrieve historical patient data, and review standing formulary policies in order to develop strategies to manage antimicrobial use and monitor resistance patterns.
In 2007, the Infectious Diseases Society of America and the Society for Health care Epidemiology of America issued its "Guidelines for Developing an Institutional Program to Enhance Antimicrobial Stew ardship." Some of these guidelines are well validated, such as optimizing antimicro bial dosing based on the individual patient, infectious agent, and site of infection. Others-such as substituting one antibiotic for another-have not yet been validated.
Research to identify new antibiotics for which resistance has not yet developed also is ongoing. However, the high cost of new drug development, combined with the more stringent approval criteria adopted in recent years by the FDA, is prohibitive for many larger pharmaceutical compa nies. The FDA's desire to prevent further resistance from emerging also means that a "new compound that makes it through reg ulatory approval will be put on a restricted list to be used only when other antibiotics have failed, thereby limiting its market," wrote Julian Davies in volume 8, number 7 (2007) of EMBO Reports.
New drug development, says Stu art Levy, a professor of molecular biology and microbiology at Tufts University, may therefore end up in the hands of academia or smaller pharmaceutical companies. "The smaller companies are able to focus on a single organism or a single product, devot ing their energies and people to that singu lar focus," he explains. "In large companies, particularly when you get to the level of animal studies, you have to wait in a queue in order to do your analysis."
Meanwhile, reining in antibiotic use is easier said than done. With cephalosporin resistance occurring at alarming rates, the FDA on 3 July 2008 proposed a withdraw al of extralabel uses of this class of anti biotics in foodproducing animals, mean ing farmers could no longer legally use these drugs for anything other than FDA approved uses listed on the label. How ever, on 25 November 2008, the agency withdrew the proposal "in order for FDA to fully consider the comments" received from groups such as the American Associa tion of Swine Veterinarians (AASV), which argued the ban was based on unsubstanti ated data. A news item in the January/ February 2009 issue of the AASV's Journal of Swine Health and Production notes that "It seems . . . that given the fact that anti microbials affect all susceptible bacteria in the animal being treated, whether or not that bacteria is on the approved label, the more rational approach would be to use an approved product for the [animal] species being treated rather than a product labeled for a different [animal] species."
The presence of antibiotic resistance genes in surface water, groundwater, at sew age treatment plants, landfills, and a variety of agricultural and aquacultural locations means pollution of the environment has not only been chemical. And although limiting antibiotic use and creating programs that control dissemination of antibiotics can pre vent the problem of resistance from worsen ing and may even reduce the problem, it's unclear whether resistant strains will neces sarily be replaced by susceptible ones, says Martínez. Moreover, says Gillings, "The natural disappearance of antibioticresistant strains is very slow-much slower than the rate of their appearance."
Still, some studies suggest that reduc ing use of antibiotics at the level of an individual medical practice is associated with reduced local antibiotic resistance. For instance, in the 1 October 2007 issue of The British Journal of General Practice, Chris C. Butler and colleagues showed that antibiotic resistance could be effectively reduced within an observable period. Specif ically, they observed an overall reduction of resistance to ampicillin (1% per year) and trimethoprim (0.6% per year) in practices that reduced their prescriptions of those drugs. Although modest, these findings may suggest the possibility of a sustained decline in resistance, wrote Butler and col leagues, thus "preserving the international reservoir of antibiotic susceptibility."
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